Capturing the Broader Value of Antibiotics
Trending
We provide independent and pioneering resources, research and analyses
Our work in health economics, health policy and health statistics informs decision-making about health care and pharmaceutical issues at a global level.
0
%
of rare diseases have a single-gene cause
0
new drugs will be approved over the next 30 years
0
molecules with potential as tumour-agnostic therapies were in development in 2019
£
0
per QALY is the range for the cost effectiveness threshold used by NICE
0
%
decrease in income for biopharma is the estimated impact of U.S. Inflation Reduction Act
0
clinical trials supported the first digital therapeutic recommended by NICE
